October 19, 2012 — Boston Scientific Corp. entered into a definitive agreement to acquire privately-held Rhythmia Medical Inc., a developer of next-generation mapping and navigation solutions for use in cardiac catheter ablations and other electrophysiology (EP) procedures.

Edwards Lifesciences announced today it received approval from the United States Food and Drug Administration (FDA) to treat high-risk aortic stenosis patients with the Edwards Sapien transcatheter aortic heart valve delivered both transfemorally and transapically (through the ribs). With the addition of high-risk patients to those eligible for the transcatheter procedure and with the approval of the transapical approach, a considerably broader group can now be treated with the Sapien valve.

Infraredx Inc., a medical device company, and Royal Philips Electronics announced they have signed a joint development and collaboration agreement that is focused on integrating Infraredx’s true vessel characterization (TVC) Imaging System with Philips’ Allura Xpercatheterization (cath) lab imaging systems. This collaboration is intended to enable seamless access to the TVC Imaging System with Philips’ Allura X-ray systems.

October 18, 2012 — Claron Technology has introduced Withinsight Framework (WIF) version 2.1, which adds advanced new segmentation tools, registration enhancements and performance improvements to the company’s innovative platform.

AngioDynamics said it entered into a definitive agreement to acquire all the outstanding capital stock of Vortex Medical Inc., a privately held company focused on the development of innovative medical devices for the removal of thrombus, or blood clots, from occluded blood vessels.

October 16, 2012 — Proteon Therapeutics Inc. has initiated enrollment in a Phase 1 clinical study of its lead product, PRT-201, in patients with symptomatic peripheral artery disease (PAD) of the superficial femoral or popliteal artery.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now